Parnax Lab — 360° view

Parnax Lab, a company in the Pharmaceuticals industry, reported revenue of ₹69 crore and net profit of ₹2.18 crore for the September 2026 quarter.

Parnax Lab (NSE: PARNAXLAB) closed at ₹114.87 on 20 Nov 2026. Its market capitalisation is ₹132 crore and it trades at 15.4 times earnings.

Share price
₹114.87 (20 Nov 2026)
Market cap
₹132 Cr (20 Nov 2026)
P/E
15.38 (20 Nov 2026)
Revenue
₹69 Cr (September 2026 quarter)
Net profit
₹2 Cr (September 2026 quarter)
ROCE
13.8% (FY26)
ROE
14.2% (FY26)
Book value
₹85.1 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹149.50 / ₹90.00 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: PARNAXLAB

Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.